Jun 2026 (Q2 FY26) — Aug 13, 2026
Xunlei Q2 FY26 — Strong Consumer-Centric Growth and Share Repurchase
Read the full callXunlei earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Price
1Y: $8.48 on 17 Oct 2025 → $4.14. High $9.4 (27 Oct 2025), low $4.14 (19 Oct 2026).
Overview
Call summaries
Xunlei Q2 FY26 — Strong Consumer-Centric Growth and Share Repurchase
Read the full callXunlei Q1 FY26 — Revenue surges 54.1% as overseas audio live streaming emerges as lead growth engine
Read the full callEvery analysed call
Financials
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -114 | -167 | -181 | -181 | -160 | -147 | -146 | 901 |
| Total liabilities | 111 | 129 | 125 | 139 | 155 | 145 | 156 | 259 |
| Fixed assets | 22 | 39 | 51 | 58 | 62 | 60 | 55 | 55 |
| Investments | 197 | 103 | 118 | 116 | 84 | 101 | 110 | 148 |
| Total assets | 455 | 425 | 416 | 441 | 463 | 469 | 474 | 1,632 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -36 | -46 | -14 | 19 | 51 | 26 | 31 | 32 |
| Cash from investing | -69 | 79 | -21 | -33 | 12 | -24 | -22 | -99 |
| Cash from financing | 1 | 12 | 3 | -0 | 7 | -14 | -1 | 45 |
| Capital expenditure | -1 | -3 | -14 | -13 | -15 | -4 | -8 | -5 |
| Free cash flow | -37 | -49 | -27 | 6 | 36 | 22 | 23 | 27 |
No filings in the last 12 months.
No officer, director or 10% owner of XNET filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow Xunlei Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading